Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety, PK, and PD of BSA204 in Chinese Adults With Borderline Elevated Lipoprotein(a)
Sponsor: Bisirna Therapeutics (Suzhou) Co., Ltd.
Summary
The purpose of this Phase 1 clinical study is to evaluate the safety and tolerability of a single dose of BSA204 injection in Chinese adults with borderline high levels of lipoprotein(a) \[Lp(a)\].
Official title: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of BSA204 Injection in Chinese Adults With Borderline Elevated Lipoprotein(a)
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-04-20
Completion Date
2027-12-31
Last Updated
2026-08-19
Healthy Volunteers
Yes
Conditions
Interventions
BSA204
BSA204 Injection
Placebo
Placebo
Locations (1)
Peking University First Hospital
Beijing, Beijing Municipality, China